Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ophthalmic Spin-Offs Alcon, AMO See Stock Gains In 2002, Join MDDI Index

This article was originally published in The Gray Sheet

Executive Summary

Ophthalmic device makers Alcon and Advanced Medical Optics (AMO) were both able to achieve double-digit stock price percentage gains in 2002 after debuting as independent firms, in part due to expanding sales of surgical products such as IOLs

You may also be interested in...



Alcon “Custom” LASIK Approval For Myopia Prohibits Superiority Claims

Alcon hopes that surgeons will accept its LADARVision CustomCornea wavefront-guided laser vision correction system as superior to currently available LASIK systems, despite FDA approval conditions prohibiting claims of superiority

AMO Surgical Devices Outshine Lens Care Products In First Earnings Report

Advanced Medical Optics' sales of intraocular lenses and phacoemulsification devices supported an 8.2% increase in ophthalmic surgical device revenue in the second quarter - the period just prior to AMO's June 29 spin-off from Allergan

Alcon To Keep R&D Focus After Spin-Off From Parent Nestle By April Via IPO

Alcon plans to spend $1.4 bil. on research and development over the next four years as an independent company, following its spin-off from Nestle

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel